AB Science Stock

AB Science Revenue

The The revenue of AB Science (AB.PA) as of Aug 17, 2026 is 1.07 M EUR. In the previous year, The revenue was 970,000.00 EUR — a change of 10.52% (higher).

Revenue

1.07 MEUR

YoY

10.52%

Last updated:

In 2026, AB Science's sales reached 1.07 M EUR, a 10.52% difference from the 970,000.00 EUR sales recorded in the previous year.

Revenue has compounded at 8.4% per year over the past 15 years to 1.07 M EUR.

The AB Science Revenue history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

REVENUE (M EUR)
GROSS MARGIN (%)
Date
REVENUE (M EUR)
GROSS MARGIN (%)
Jan 1, 2020
1.58 base
95.64 base
Jan 1, 2021
1.61 base
93.09 base
Jan 1, 2022
0.96 base
96.76 base
Jan 1, 2023
0.97 base
60.52 base
Jan 1, 2024
1.07 base
116.42 base
Jan 1, 2025 (e)
1.10 base
113.56 base
Jan 1, 2026 (e)
1.13 base
110.15 base
Jan 1, 2027 (e)
1.34 base
93.20 base
YEARREVENUE (M EUR)GROSS MARGIN (%)
2027 est 1.3493.20
2026 est 1.13110.15
2025 est 1.10113.56
2024 1.07116.42
2023 0.9760.52
2022 0.9696.76
2021 1.6193.09
2020 1.5895.64
2019 1.5788.48
2018 1.7085.42
2017 1.7493.04
2016 1.5169.96
2015 2.2885.16
2014 2.1081.43
2013 1.9382.90
2012 1.3482.09
2011 1.1072.73
2010 1.1867.80
2009 0.3253.13
2008 --
2007 --
Access this data via the Eulerpool API
Get Free API Key

AB Science Revenue

AB Science Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2020
1.58 M EUR
-14.75 M EUR
-15.05 M EUR
Jan 1, 2021
1.61 M EUR
-13.81 M EUR
-14.46 M EUR
Jan 1, 2022
958,000.00 EUR
-15.94 M EUR
-13.62 M EUR
Jan 1, 2023
970,000.00 EUR
-13.43 M EUR
-11.99 M EUR
Jan 1, 2024
1.07 M EUR
-6.08 M EUR
-7.83 M EUR
Jan 1, 2025 (e)
1.10 M EUR
-22.42 M EUR
-8.86 M EUR
Jan 1, 2026 (e)
1.13 M EUR
-22.73 M EUR
-8.18 M EUR
Jan 1, 2027 (e)
1.34 M EUR
0.00 EUR
0.00 EUR

AB Science Margins

AB Science stock margins

The AB Science margin analysis displays the gross margin, EBIT margin, as well as the profit margin of AB Science. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for AB Science.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2020
95.64 %
-931.71 %
-950.41 %
Jan 1, 2021
93.09 %
-859.24 %
-900.00 %
Jan 1, 2022
96.76 %
-1,663.57 %
-1,421.19 %
Jan 1, 2023
60.52 %
-1,384.43 %
-1,235.57 %
Jan 1, 2024
116.42 %
-567.44 %
-730.50 %
Jan 1, 2025 (e)
116.42 %
-2,040.32 %
-806.32 %
Jan 1, 2026 (e)
116.42 %
-2,006.36 %
-721.96 %
Jan 1, 2027 (e)
116.42 %
0.00 %
0.00 %

AB Science Stock analysis

What does AB Science do? AB Science SA is a biopharmaceutical company based in France that specializes in developing therapies for diseases with high medical need and unmet medical demand. The company was founded in 2001 by Alain Moussy and went public on the Paris stock exchange Euronext in 2010. AB Science SA's business model involves independently conducting research and development of new drugs while also building partnerships with other companies or institutions to optimize the value chain from research to commercialization. AB Science SA is divided into different divisions to specifically address the disease areas to be treated, including oncology and neurology. The company aims to develop innovative drugs based on scientific knowledge that meet the needs of patients suffering from severe and complex diseases. An important aspect of AB Science SA's product range is the quality of the products, with the company working on developing effective and safe therapies. A key component of AB Science SA's product range is the tyrosine kinase inhibitor masitinib. This is used in veterinary medicine and is intended to be used in both dogs and cats suffering from allergic, inflammatory, and oncological diseases. Masitinib is a selective inhibitor of tyrosine kinase that contributes to the regulation of signaling pathways found in cancer cells. It is believed that masitinib plays an important role in modulating the immune system and inhibiting cancer cells, although further studies are needed to confirm the potential therapeutic applications of masitinib. AB Science SA has made significant progress in oncology, particularly in the treatment of gastrointestinal stromal tumors and certain types of malignant tumors that are rare forms of cancer. AB Science SA has now submitted both products for an extended approval request (EA) in collaboration with US Regulatory, achieving the most significant success in the company's history. This could expedite the approval of these two products in the United States. In neurology, AB Science SA has also made significant progress and is currently developing products for the treatment of Alzheimer's disease, multiple sclerosis, and Parkinson's disease. In all of these areas, there is a significant unmet need for safe and effective medications, and AB Science SA is committed to addressing this need through the development of innovative therapies. Overall, AB Science SA is a biopharmaceutical company specializing in the development of therapies to combat diseases with high unmet medical needs. In addition to independent research and development, the company aims to build partnerships with other companies and institutions to optimize the value chain from research to commercialization. The main divisions of the company are oncology and neurology, and it has made significant progress in both areas. The increased submission of approval requests is a significant milestone in the company's history and could lead to further advancement within the industry. AB Science is one of the most popular companies on Eulerpool.

Revenue Details

Understanding AB Science's Sales Figures

The sales figures of AB Science originate from the total revenue accrued from goods sold or services provided during a specific time period. These numbers are a direct reflection of the company’s ability to translate its products or services into revenue, indicating the demand and market presence.

Year-to-Year Comparison

Analyzing AB Science’s yearly sales data offers insights into the company’s growth and stability. An increase in sales suggests a growing demand for its offerings, efficient marketing, or expansion into new markets. Conversely, a decline might indicate market saturation, increased competition, or less effective strategies.

Impact on Investments

Investors often scrutinize AB Science's sales data to evaluate its financial health and growth prospects. Consistent sales growth can be a promising indicator of the company’s profitability and potential return on investment, influencing stock prices and investor confidence.

Interpreting Sales Fluctuations

Increases in AB Science’s sales indicate market growth, innovation, or effective marketing, often leading to a surge in stock prices. A decline, however, can signal challenges requiring strategic adjustments to enhance market share and profitability.

Frequently Asked Questions about AB Science stock

The revenue of AB Science is 1.07 M EUR in 2026.

The revenue of AB Science changed from 970,000.00 EUR to 1.07 M EUR, representing a 10.52% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of The revenue AB Science since 2006 – with annual values, charts, and detailed analysis.

Revenue is the total value of all goods sold in a period. It is calculated by multiplying the quantity of each product sold by its selling price. Revenue does not include any costs (material costs, personnel costs, etc.), whereas net proceeds only deduct revenue reductions associated with the sale (discounts, etc.).

The revenue's EUR is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track The revenue's AB Science historically and in real time.

The revenue in assessing a stock

Revenue is an important financial measure used in the valuation of stocks. It is a measure of a company's economic activity and can serve as an indicator of the company's success. Revenue is considered one of the most important factors in stock valuation. In addition, revenue can also be used to calculate other financial measures such as earnings per share and price-earnings ratio.

History and utilization of revenue

Revenue has long been considered one of the most important financial indicators. It was used in the 19th century as one of the first financial indicators to measure a company's economic activity. Since then, revenue has been regularly used to evaluate companies.

Revenue is usually calculated as a percentage of the company's equity. It can also be used to determine the overall profitability of a company. There are many different types of revenue that can be used to measure a company's economic activity, such as gross revenue, net revenue, and revenue from international business.

The revenue can also be used to evaluate stocks. For example, the revenue of a company can be used to evaluate the success of the company. If a company has high revenue, it means that it is a profitable company because it has high demand for its products or services.

Calculation and Application of Revenue

In order to calculate a company's revenue, the company's income must be deducted from its expenses. The income can come from various sources, such as sales, licensing fees, services, etc. The expenses can include costs for production, procurement, inventory, sales, and administration.

The revenue can then be used to calculate various financial ratios. For example, the revenue can be used to calculate the price-earnings ratio (P/E ratio) of a company. This is a measure of a company's profitability, calculated by taking the ratio of the stock price to earnings per share.

Revenue can also be used to calculate earnings per share (EPS) of a company. This is a measure of a company's profit per share. EPS is calculated by dividing earnings by the number of shares issued.

Use of revenue by investors

Investors use revenue to evaluate stocks, as revenue is an indicator of a company's success. For example, an investor can compare a company's revenue to see how successful it is. An investor can also use a company's revenue to calculate its price-to-earnings ratio and earnings per share.

An example: An investor looks at a company that has a revenue of 25 million euros. He compares this revenue to that of the competitor, which has a revenue of 35 million euros. The investor can then see that the company with 25 million euros in revenue is less successful than the company with 35 million euros in revenue.

Advantages and Disadvantages of Revenue.

Revenue is a very useful tool for valuing stocks as it measures a company's economic activity. Revenue can also be used to calculate other financial ratios such as the price-earnings ratio and earnings per share.

However, one disadvantage is that revenue alone is not a meaningful indicator of a company's success. It is important to consider revenue in comparison to other financial metrics such as earnings per share and price-to-earnings ratio to get a complete picture of the company.

Access this data via the Eulerpool API
Get Free API Key

Income Statement — AB Science

RevenueGross ProfitEBITEBITDANet IncomeEPSCost of Goods SoldR&D ExpensesSG&A ExpensesOperating ExpensesInterest ExpensePretax IncomeTax ExpenseDepreciation & AmortizationRevenue per ShareEBIT per ShareDiluted EPSEBITDA per ShareOther Income/Expense

All Key Metrics — AB Science